ReutersCodex · 实盘可交易 · 做多市场:美股▲ 赚 +1.09% · 已结算把握 5/10
北京时间·🕒 发布 06:45:07时区推断·⟳ 抓取 10:56:10·⚡ 决策 07-02 12:06:41 +1h10m·117.2 天前
FDA批准Vertex/CRISPR的Casgevy扩展用于2岁及以上镰状细胞病和输血依赖型β地中海贫血患者
FDA和Vertex官网均在2026-07-01确认Casgevy补充适应症获批，年龄从12岁以上扩展到2岁以上，是明确的一手监管催化。
📄 原文Reuters↗ 原文
The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' (VRTX.O) gene therapy in childre…
▲ 赚 +1.09%入场 07-01 盘后首笔 @55.40 → 离场 07-02 常规开盘 @56.18
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑FDA和Vertex官网均在2026-07-01确认Casgevy补充适应症获批，年龄从12岁以上扩展到2岁以上，是明确的一手监管催化。
怎么买 开盘买入 不高于昨收 +4%（超上限不成交）
怎么卖 止盈 +8%(半仓)/+16%(清仓) · 止损 -7% · 时间止损 3日
失效/反转 若公司或监管后续披露儿科标签实际覆盖、医保支付或治疗中心准入明显受限，或开盘高开超过前收4%导致风险收益失衡，则不追单。
不做 Vertex Pharmaceuticals（VRTX.US）
Vertex Pharmaceuticals（VRTX.US）虽为直接受益方，但公司收入和市值体量大，Casgevy儿科扩龄对短期估值弹性弱于CRISPR Therapeutics（CRSP.US），本次不作为主交易腿。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 CRSP.US CRISPR Therapeutics
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 CRSP.US CRISPR Therapeutics
| 收益状态 | +1.09% 已平仓 |
|---|---|
| 进场成交 | 2026-07-01 · 盘后首笔 · 07-02 06:50 北京 · @55.4 · 成交 0% |
| 离场成交 | 2026-07-02 · 常规开盘 · @56.18 |
| 毛收益 | +1.41% |
| 成本 | +0.32% |
| 净收益 | +1.09% |
| 计入收益 | +0.00% |
| 计入 | 同日重复,不计入曲线 |
| 建仓日 | 2026-07-01 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-27 16:34
研究档案
关键理由
- FDA和Vertex官网均在2026-07-01确认Casgevy补充适应症获批，年龄从12岁以上扩展到2岁以上，是明确的一手监管催化。
- CRISPR Therapeutics（CRSP.US）按Casgevy全球项目享有40%利润/亏损分成，较Vertex Pharmaceuticals（VRTX.US）市值和收入体量更小，对同一产品进展的股价弹性更高。
- CRISPR Therapeutics（CRSP.US）截至2026-07-01收55.62美元、当日仅涨2.0%，事件发生在美股盘后，尚未经历完整正常交易时段重定价，balanced档位下适合小仓开盘参与。
主要风险
- 儿童适应症扩展的商业放量仍受基因治疗中心、医保支付、采集和移植流程约束，短期收入贡献可能慢于标题反应。
- 6月中旬Vertex已披露美国儿科扩展审评在推进并获Priority Voucher，审批本身有一定预期，price-in风险不低。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-05-05 · 影响 weakens
CRISPR Therapeutics一季度仍为净亏损，Casgevy贡献改善但尚未改变公司整体亏损状态，商业化节奏仍是主要反证。
检索:CRSP Casgevy revenue royalties Vertex recent risks earnings downgrade safety 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-06-12 · 影响 weakens
儿科扩展申报和加速审评此前已公开，审批结果虽为新信息，但不是完全低预期差催化。
检索:Vertex Casgevy pediatric expansion priority voucher June 2026 原文 ↗
原文全文
展开原文 · 1,567 字
The U.S. Food and Drug Administration approved expanded use of Vertex Pharmaceuticals' (VRTX.O) gene therapy in children as young as two with inherited blood disorders, including sickle cell disease, the first such treatment cleared for this age group.
Casgevy, a one-time treatment made from a patient's own blood stem cells, was previously approved for patients aged 12 and older with sickle cell disease or transfusion-dependent beta thalassemia.
Here are further details: -
Sickle cell disease is a painful, inherited blood disorder in which the body makes sickle-shaped hemoglobin, preventing red blood cells from properly carrying oxygen to the body's tissues.
In a trial of children aged five to under 12 with sickle cell disease, all eight evaluable patients had no severe vaso-occlusive crises or painful episodes for at least 12 straight months within the first 24 months of infusion.
In beta thalassemia, eight of nine evaluable children achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months.
The FDA granted approval to Vertex in 53 days after filing under the Commissioner's National Priority Voucher, its new fast-track program designed to shorten review time for a drug application.
In 2023, the FDA approved Vertex's and Genetix Biotherapeutics' gene therapies for sickle cell disease in patients 12 years and older.
Other long-term treatment options for sickle cell disease include bone marrow transplant, which requires matching donors, and the chemotherapy drug hydroxyurea.
Casgevy, a one-time treatment made from a patient's own blood stem cells, was previously approved for patients aged 12 and older with sickle cell disease or transfusion-dependent beta thalassemia.
Here are further details: -
Sickle cell disease is a painful, inherited blood disorder in which the body makes sickle-shaped hemoglobin, preventing red blood cells from properly carrying oxygen to the body's tissues.
In a trial of children aged five to under 12 with sickle cell disease, all eight evaluable patients had no severe vaso-occlusive crises or painful episodes for at least 12 straight months within the first 24 months of infusion.
In beta thalassemia, eight of nine evaluable children achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months.
The FDA granted approval to Vertex in 53 days after filing under the Commissioner's National Priority Voucher, its new fast-track program designed to shorten review time for a drug application.
In 2023, the FDA approved Vertex's and Genetix Biotherapeutics' gene therapies for sickle cell disease in patients 12 years and older.
Other long-term treatment options for sickle cell disease include bone marrow transplant, which requires matching donors, and the chemotherapy drug hydroxyurea.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。